myocardial gene therapy
gene therapy proving likely viable alternative conventional therapies coronary artery disease heart failure phase clinical trials indicate high levels safety clinical benefits gene therapy using angiogenic growth factors myocardial ischaemia although gene therapy heart failure still pre-clinical stage experimental data indicate therapeutic angiogenesis using short-term gene expression may elicit functional improvement affected individuals
